|
|
|
|
|
|
|
CorMedix- Inc. (CRMD)
|
|
0.2751 0.017 (6.63%)
|
07-19 15:28
|
|
Open:
|
0.264
|
Pre. Close:
|
0.258
|
|
High:
|
0.276
|
Low:
|
0.26
|
|
Volume:
|
396,055
|
Market Cap:
|
23M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
0.27 - 0.272
|
0.272 - 0.273
|
|
Low:
|
0.247 - 0.248
|
0.248 - 0.25
|
|
Close:
|
0.258 - 0.26
|
0.26 - 0.262
|
|
|
|
Technical analysis (as of: 2018-07-19 2:20:22 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a BUY today, upgraded from lower rating. This stock seems to be ready for a new bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, a new upward move is expected.
|
|
Target:
|
Six months: 0.39 One year: 0.45
|
|
Support:
|
Support1: 0.26 Support2: 0.21
|
|
Resistance:
|
Resistance1:
0.33 Resistance2: 0.39
|
|
Pivot:
|
0.26
|
|
Moving Averages:
|
MA(5): 0.26 MA(20): 0.25
MA(100): 0.24  MA(250): 0.40
|
|
MACD:
|
MACD(12,26):
0.01 Signal(12,26,9):
|
|
%K %D:
|
%K(14,3): 68.75 %D(3): 65.97
|
|
RSI:
|
RSI(14): 55.34
|
|
52-Week:
|
High: 0.78
Low: 0.17 Change(%): -32.9
|
|
Average Vol(K):
|
3-Month: 142390
10-Days 109135
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.CRMD has closed below upper band by 23.7%. Bollinger Bands are 46.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to CRMD's normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
|
|
|
Headline News
|
|
2018-05-16T05:51:44-04:00
CorMedix misses by $0.04, misses on revenue
2018-05-15T20:26:03-04:00
CorMedix's (CRMD) CEO Khoso Baluch on Q1 2018 Results - Earnings Call Transcript
2018-03-19T20:37:05-04:00
CorMedix's (CRMD) CEO Khoso Baluch on Q4 2017 Results - Earnings Call Transcript
2018-02-02T14:05:33-05:00
CorMedix Drug Candidate Lauded By FDA, Approved In The EU, Could Treat Deadly Pathogen Feared By CDC
2017-12-17T16:15:23-05:00
Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold
2017-11-11T13:48:05-05:00
CorMedix's (CRMD) CEO Khoso Baluch on Q3 2017 Results - Earnings Call Transcript
2017-11-10T07:41:25-05:00
CorMedix misses by $0.04, beats on revenue
2017-09-25T09:11:39-04:00
Premarket analyst action - healthcare
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
